Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6673651 | 0.94 | KCNH2 (0.40) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7093068 | 0.92 | KCNH2 (0.39) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6669435 | 0.92 | KCNH2 (0.40) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6669737 | 0.91 | KCNH2 (0.41) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6671726 | 0.91 | KCNH2 (0.36) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6671601 | 0.90 | KCNH2 (0.40) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6684184 | 0.89 | KCNH2 (0.38) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6668829 | 0.88 | KCNH2 (0.37) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7094274 | 0.87 | KCNH2 (0.39) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6674177 | 0.87 | KCNH2 (0.37) | KCNH2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | claimed |
| EP-1401830-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | KCNH2 143/4885CYP1A2 366/4885CYP3A4 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.